-
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Tuesday, July 16, 2024 - 3:07pm | 943Johnson & Johnson (NYSE:JNJ) was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17....
-
New Study Looks At Obscure Cannabinoids For Treating Psoriasis, Eczema And Acne
Friday, August 25, 2023 - 3:23pm | 445A new study suggests that some lesser-known cannabinoids in hemp and marijuana can help with common skin conditions like psoriasis, eczema and acne. A study published by the journal 'Molecules' aptly notes, “Dermatological diseases pose a significant burden on the...
-
The Key To Perfect Hair? Myths And Benefits Of CBD For Hair Care
Sunday, May 28, 2023 - 12:19pm | 747This article was originally published on The Fresh Toast and appears here with permission. Ads are everywhere about making your hair more luxe, thicker, shiner, and just perfect! The hair care product industry is worth over $75 Billion globally and that excludes hairdressers,...
-
Roivant' Dermavant Showcases New Long-Term Durability, Tolerability Data For Plaque Psoriasis Candidate
Friday, March 25, 2022 - 10:19am | 249Roivant Sciences Ltd's (NASDAQ: ROIV) subsidiary Dermavant Sciences announced results from Phase 3 PSOARING 3 long-term extension study of tapinarof cream 1% for plaque psoriasis in adults. The results demonstrated durable improvements across efficacy outcomes, quality...
-
Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study
Tuesday, March 8, 2022 - 9:35am | 335Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort study of Piclidenoson in severe plaque psoriasis would be released in Q2 2022. Earlier, the data were anticipated in Q1 of 2022....
-
Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know
Monday, February 7, 2022 - 9:58am | 367Dermata Therapeutics Inc (NASDAQ: DRMA) has requested the FDA to waive the requirements to complete a 90-day dermal minipig study and a standard dermal pharmacokinetics study before the End of Phase 2 meeting for its DMT310 acne program. The Company said it has already planned...
-
Can Fite's Piclidenoson Destroys Pathological Skin Cells, Lab Study Shows
Thursday, January 13, 2022 - 9:44am | 286Can-Fite BioPharma Ltd (NYSE: CANF) announced preclinical studies with skin cells, modeling psoriasis in humans, showing that Piclidenoson destroys pathological skin cells. Piclidenoson is the company's lead drug candidate for the treatment of psoriasis. The company's...
-
Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast
Thursday, December 23, 2021 - 11:17am | 230Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has obtained a $225 million term loan facility from SLR Capital Partners (SLR). This additional capital further strengthens Arcutis' balance sheet before a potential 2022 FDA approval & launch of topical roflumilast...
-
Arcutis' Roflumilast Cream For Psoriasis Goes Under FDA Review
Thursday, December 23, 2021 - 9:51am | 246The FDA has accepted Arcutis Biotherapeutics Inc's (NASDAQ: ARQT) marketing application seeking approval for roflumilast cream for psoriasis in adults and adolescents. The FDA assigned the application a Prescription Drug User Fee Act target action date of July 29, 2022....
-
Amgen's Otezla Wins FDA Approval For Psoriasis, Regardless Of Severity Level
Tuesday, December 21, 2021 - 10:05am | 257The FDA has approved Amgen Inc's (NASDAQ: AMGN) Otezla (apremilast) to treat adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. With this expanded indication, Otezla is now the first and only oral treatment approved in adult...
-
Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022
Tuesday, December 7, 2021 - 9:32am | 281Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last of approximately 400 psoriasis patients enrolled in its Phase 3 Comfort study is scheduled to complete a 16-week cycle of treatment with Piclidenoson at the beginning of January 2022. Piclidenoson is a novel, first-in-...
-
vTv Therapeutics Pulls The Plug On Psoriasis Candidate; Cuts Workforce By 65%
Tuesday, December 7, 2021 - 6:43am | 326vTv Therapeutics Inc (NASDAQ: VTVT) has decided to shift focus and prioritize its lead program TTP399 as it gears up for Phase 3 pivotal trials. See the pipeline here. As a part of the restructuring, the company will reduce its workforce by approximately 65%. The company also...
-
Amgen's Otezla Meets Primary Goal In Late-Stage Genital Psoriasis Study
Thursday, December 2, 2021 - 7:21am | 269Amgen Inc (NASDAQ: AMGN) announced topline results from the DISCREET trial Phase 3 trial of Otezla (apremilast) in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis. The study showed that oral Otezla 30 mg twice daily achieved a...
-
Bristol Myers' Deucravacitinib Under FDA Review For Plaque Psoriasis
Monday, November 29, 2021 - 10:37am | 261The FDA has accepted for review Bristol Myers Squibb & Co's (NYSE: BMY) deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis. The European Medicines Agency has also validated the deucravacitinib marketing application for plaque...
-
Zai Lab Posts Encouraging Data From Early-Stage Plaque Psoriasis Trial
Thursday, October 21, 2021 - 6:11am | 306Zai Lab Limited (NASDAQ: ZLAB) announced topline results from Phase 1b study of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP). ZL-1102 is an investigational, novel human VH antibody fragment targeting the IL-17A cytokine. In efficacy...